Two projects have been accepted into the Institut Pasteur Innovation Accelerator, an initiative to improve the development potential of the Institut Pasteur's research: a highly automated technological system involving bioassays and a partnership based on a French startup studio.
-
The Institut Pasteur will be setting up the project Pfbioassays [in French] (Thierry Rose and Sébastien Quesney), funded by the French government and the Greater Paris Region, on its campus. The aim of the project is to develop a highly automated technological bioassay system involving the packaging and analysis of serum samples. This new system, based on state-of-the-art technologies, will contribute to epidemiological, clinical and scientific studies and facilitate the development of innovative bioassays using groundbreaking technologies.
Find out more on the Greater Paris Region website [in French]
-
The Institut Pasteur is also a scientific partner for the launch of Argobio Studio [in French], a French startup studio specializing in the creation and development of promising biotech companies. The aim of Argobio will be to incubate highly innovative projects in a selection of therapeutic fields, from the early stages of their development to company startup and funding.
In 2019, the Institut Pasteur Innovation Accelerator was launched to improve the development potential of research activities. In its 2019-2023 Strategic Plan, the Institut Pasteur pledged to maintain a detailed knowledge of all its research projects so that it would be able to identify any potential applications and accelerate the potential for innovation development.
The programs in the Institut Pasteur Innovation Accelerator are divided into four fields: diagnostics, technologies, therapeutics and vaccines. Efforts are focused on key projects certified by an independent committee. In 2020, four programs were selected out of the 83 initially submitted :
- A blocking antibody, targeting human activating IgG receptor, CD16 (FcγRIII), to treat and prevent thrombocytopenia: Pierre Bruhns
- New epigenetic inhibitors of P. falciparum blood stage infection active in Cambodia resistant strains and in a rodent malaria model: Paola Arimondo / Artur Scherf.
- HPV RNA-Seq a novel and unique molecular screening test that allows detection of pre-cancerous lesions of the cervix from cervical samples: Marc Eloit.
- Improved dengue diagnosis and prognosis: the value of a novel complex formed between dengue virus NS1 and human high-density lipoproteins: Marie Flamand
